Translational Sciences (NCATS) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

ADDRESSES: Submissions may be sent electronically to *DK-IDG-Phase2-RFI@mail.nih.gov* or by mail to Dr. Karlie Sharma, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892.

FOR FURTHER INFORMATION CONTACT: Questions about this request for information should be directed to Dr. Karlie Sharma, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892, *DK-IDG-Phase2-RFI@mail.nih.gov,* 301–451–4965.

SUPPLEMENTARY INFORMATION: Out of the nearly 30,000 genes in the human genome, approximately 3,000 genes are estimated to be part of the druggable genome—the subset of genes expressing proteins with the ability to bind drug-like molecules. Yet, only about ten percent of druggable proteins are targeted by Food and Drug Administration (FDA)-approved drugs. Many proteins that comprise the druggable genome are members of the G-protein coupled receptor (GPCR), ion channel, and kinase families. A significant number of proteins within these classes are understudied and are the focus of the data and resource generation initiative of the IDG Program.

1. Goals and Requirements

The IDG Program was originally funded as a three-year pilot program in 2014 with two overarching goals: (1) Integrate information about understudied druggable proteins from disparate sources into a single informatics site and (2) foster technology development to enable the determination of function and therapeutic potential of understudied druggable proteins. Having successfully achieved these goals, the IDG Program is currently transitioning to a new implementation phase intended to:

- Expand the informatics tools developed in the pilot phase to include additional data and allow users to access, analyze, and visualize a wide range of information on sets of proteins.
- Facilitate the elucidation of the function of understudied proteins from the three key druggable protein families (GPCR, ion channels, and kinases) by generating new reagents and new data.
- Disseminate the IDG-generated resources and data to the greater scientific community.

2. Information Requested

NIH is seeking input from national and international experts and interested members of the public that includes, but is not limited to, the following areas:

- Resources that an outside organization (biotechnology or pharmaceutical company; non-profit organization; academic institution and national/international consortia) might be willing to share with the IDG Program and may:
  - Strategize development of chemical probes against proteins drawn from the IDG focused list
  - develop assays and platforms that can help to answer questions about understudied protein function
  - identify reagents that may be useful in annotation efforts
  - provide data or knowledge on any understudied protein
- Potential resources of the IDG Program that are of interest to an outside organization of the broader biomedical research community including:
  - Sharable databases of relevant subsets of data on understudied proteins
  - data analysis and query tools
  - links between protein target and disease pathologies
  - new methods of analysis to accelerate collection of data

This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States Federal government. The Federal government will not pay for the preparation of any information submitted or for the government's use. Additionally, the government cannot guarantee the confidentiality of the information provided.

Dated: April 12, 2017.

Christopher P. Austin,

Director, NCATS.

Griffin P. Rodgers,

Director, NIDDK, Illuminating the Druggable Genome Program, National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases.

[FR Doc. 2017–07795 Filed 4–17–17; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVCES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed project or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer at (240) 276–1243.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project: Strategic Prevention Framework for Prescription Drugs (SPF-Rx)—New

The Substance Abuse and Mental Health Services Administration (SAMHSA)'s Center for Substance Abuse Prevention (CSAP) aims to conduct a cross-site evaluation of the Strategic Prevention Framework for Prescription Drugs (SPF-Rx) program. The SPF-Rx program is designed to address nonmedical use of prescription drugs (as well as opioid overdoses) by raising awareness about the dangers of sharing medications. and by working with pharmaceutical and medical communities. The SPF-Rx program aims to promote collaboration between states/tribes and pharmaceutical and medical communities to understand the risks of overprescribing to youth ages 12–17 and adults 18 years of age and older. The program also aims to enhance capacity for, and access to, Prescription Drug Monitoring Program (PDMP) data for prevention purposes.

The SPF-Rx program aims to address SAMHSA's priorities on prevention and

reduction of prescription drug and illicit opioid misuse and abuse. Its indicators of success are reductions in opioid overdoses and the incorporation of PDMP data into needs assessments and strategic plans. Data collected through the tools described in this statement will be used for the national cross-site evaluation of SAMHSA's SPF-Rx program. This package covers continued data collection through 2020, as the evaluation is expected to continue through at least that time; however, the Program Evaluation for Prevention Contract (PEP–C) is scheduled to conduct a national cross-site evaluation of SPF-Rx through September 2018. The PEP–C team will systematically collect and maintain an Annual Implementation Instrument (AII) and outcomes data submitted by SPF-Rx grantees through the online PEP–C Management Reporting Tool (MRT).

SAMHSA is requesting approval for data collection for the SPF-Rx cross-site evaluation with the following four instruments:

• *Grantee Interview* to obtain the perspective of the implementing Project Directors (PDs) or their staff on important topics, including infrastructure and capacity, collaboration, leveraging funding and resources, criteria and use of evidence-informed interventions, monitoring and evaluation, collaboration, challenges, and health disparities. Information from these interviews will help inform SPF-Rx cross-site evaluation reports and will help identify lessons learned and success stories from grantees' SPF-Rx programs.

• *Grantee- and Community-Level Outcomes Modules* to collect data on key SPF-Rx program outcomes, including opioid misuse and abuse, opioid overdoses, and opioid prescribing patterns. Grantees will provide outcomes data at the grantee level for their state, tribal area, or jurisdiction, as well as at the community level for each of their subrecipient communities.

• *Substitute Data Source Request* to allow grantees to request permission from SAMHSA to use ''substitute measures'' for their outcomes data—that is, measures that differ from a list of preapproved outcomes measures.

• *Annual Implementation Instrument* to collect data completed by grantees and subrecipient community PDs. Data collected from the survey will be used to monitor subrecipient and state, tribal entity, or jurisdiction performance, and to evaluate the effectiveness of the SPF-Rx program across states, tribal entities, and jurisdictions.

• *Grantee Interview* to collect semistructured telephone interview data to gather more in-depth information on organizational infrastructure, use of PDMP data.

• *Evaluation Plan* to allow grantees to outline their local evaluation plan. This section should include goals and objectives, performance measures, a data analysis plan, and reporting plan.

ANNUALIZED DATA COLLECTION BURDEN

Instrument	Number of respondents	Responses per respondent	Total number of responses	Hours per response	Total burden hours
Grantee-Level Outcomes Module	25	1	25	3	75
Community-Level Outcomes Module	25	1	25	3	75
Substitute Data Request Form	3.67	1	3.67	1	3.67
Annual Implementation Instrument	100	1	100	2.3	230
Grantee-Level Interview	17	1	17	1.5	25.5
Evaluation Plan	25	1	25	8	200
Overall Total	170.67		170.67		609.17

Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost over the 3 years (FY2018–FY2020).

Send comments to Summer King, SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Room 15E57–B, Rockville, Maryland 20857, *OR* email a copy to *summer.king@samhsa.hhs.gov.* Written comments should be received by June 19, 2017.

Summer King,

Statistician.

[FR Doc. 2017–07764 Filed 4–17–17; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[LLCAN01000 L10200000.XZ0000 17X LXSIOVHD0000]

Notice of Public Meeting: Northern California District Resource Advisory Council

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

SUMMARY: In accordance with the Federal Land Policy and Management Act of 1976, and the Federal Advisory Committee Act of 1972, the U.S. Department of the Interior, Bureau of Land Management's (BLM) Northern California District Resource Advisory Council (RAC) will meet as indicated below.

DATES: The meeting will be held on Wednesday, April 26, 2017, from 10 a.m. to 4 p.m. The meeting is open to the public. Public comments will be accepted at 11 a.m. to noon.

ADDRESSES: The meeting will be held in the conference room of the Bureau of Land Management Northern California District Office, 6640 Lockheed Drive, Redding, CA 96002. Those unable to attend can participate by teleconference. The toll-free telephone number is (888) 282–0374, and the passcode is 50716. Written comments can be sent to the district office at the above address.

FOR FURTHER INFORMATION CONTACT: BLM Northern California District Manager, Alan Bittner, (530) 224–2160; or Public Affairs Officer, Joseph J. Fontana, (530) 252–5332. Persons who use a telecommunications device for the deaf may call the Federal Relay Service at 800–877–8339, to contact the above individuals during normal business hours. The Service is available 24 hours a day, 7 days a week, to leave a message or question with the above individual.